The intent of this review is to provide a concise overview of all recent acquisitions in terms of therapies and early noninvasive diagnostic approaches for nonalcoholic fatty liver disease (NAFLD) in children. Recent findings NAFLD is increasingly being diagnosed in children. If undiscovered and if certain risks are present (i.e. obesity), nonalcoholic steatohepatitis, the most severe form of NAFLD, may silently progress to cirrhosis, hepatocarcinoma and liver-related death in adulthood. Current therapies include approaches for reducing the incidence of risk factors (i.e. weight reduction), drugs targeting the major molecular mechanisms thought essential in the pathogenesis of the disease (insulin resistance and oxidative stress) or both, but other novel treatments are under investigation. Summary Although weight reduction, achieved through a combination of diet and exercise, makes it possible to modify the natural course of simple steatosis, the addition of adequate drugs might also provide a therapeutic action on nonalcoholic steatohepatitis. Moreover, preventive strategies and the design and translation into clinical practice of indices that integrate noninvasive diagnostic tools and serum biomarkers might be a winning approach for improving management of paediatric NAFLD/nonalcoholic steatohepatitis in the coming years.
Introduction
Nonalcoholic fatty liver disease (NAFLD) includes a broad spectrum of liver abnormalities ranging from accumulation of fat (simple steatosis) to nonalcoholic steatohepatitis (NASH) with various degrees of necroinflammation and fibrosis. As in adults, steatosis, ballooning, inflammation and fibrosis are the main histological findings in paediatric NAFLD. However, diagnosis of paediatric NASH can be difficult because of the heterogeneity of paediatric NASH subphenotypes [1, 2] .
Paediatric NAFLD has a worldwide distribution and its incidence continues to rise, paralleling the epidemic of obesity [3, 4] . In the face of such an epidemic trend, there is an urgent need for early diagnostic means to evaluate grade and stage of the disease, as well as for well tolerated and effective therapeutic approaches for NASH (i.e. the presence of mild and severe fibrosis) [5 ,6 ] .
At present, the precise prevalence of NASH in children remains unknown, mainly because serum biomarkers for revealing steatohepatitis and fibrosis are often not used and a definitive diagnosis of NASH is exclusively based on liver biopsy. In addition, because of the limited knowledge of the pathogenic mechanism(s) leading to fatty liver, necroinflammation and fibrosis, the current therapeutic modalities include strategies for reducing the incidence of risk factors (obesity, insulin resistance and diabetes), drugs targeting the major pathways thought essential in the pathogenesis of the disease or both [7, 8] .
The current article reviews the criteria for management (diagnosis and therapy) of patients with NAFLD and describes the most recent acquisitions and their possible use in an early, noninvasive diagnosis and treatment of NASH and fibrosis.
What is nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis and how common is it in children?
NAFLD/NASH in children was described for the first time in 1983 [9] . As in adults, the diagnosis of paediatric NASH, which is the most advanced form of NAFLD, requires characteristic histological lesions, including steatosis, ballooning degeneration and lobular inflammation with or without fibrosis [10, 11] . However, the histological pattern of NAFLD in children may be either similar to, or quite disparate from, those of adults, in terms of type and distribution of lesions [12, 13] . In fact, children not only present the adult-like type 1 NAFLD, mainly characterized by steatosis in zone 3, but also two other forms: type 2 NAFLD, characterized by panacinar steatosis or accentuation of steatosis in zone 1, zero to minimal hepatocellular ballooning with or without portal inflammation and fibrosis; and 'overlap type' [12, 13] .
It is well documented that fatty liver and steatohepatitis may occur in very young children [12, 13] . As with adults, paediatric NAFLD represents only a small but definite risk of cirrhosis. In fact, there are only a few series [14] [15] [16] that reported the development of childhood or young adulthood cirrhosis in paediatric patients with NAFLD. Interestingly, in a recent cohort study, Feldstein et al.
[17 ] determined a long-term (20 years) prognosis of 66 patients, demonstrating that children with NAFLD may progress to cirrhosis and end-stage liver disease, thus requiring liver transplantation.
Although NAFLD has nowadays reached epidemic proportions, its real prevalence remains unknown. The prevalence of NAFLD in the general population in Western countries was indirectly estimated as being between 20 and 40%. These values rise dramatically, reaching values between 70 and 80%, in individuals particularly predisposed to the disease (e.g. obesity and diabetes) [18 ] . Similarly, the prevalence of NAFLD is growing among children and adolescents; in fact, among children, in general, it affects approximately 3-10%, whereas in obese children this percentage ranges between 20 and 53% [19 ].
However, a realistic estimate of the true current prevalence of paediatric NASH can be obtained only in obese children, who are referred to secondary care centres for the treatment of obesity. In two recent large studies [15, 20] , NASH is diagnosed in 68 and 84% of NAFLD children, respectively, from the San Diego and Rome survey.
What are the causes of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis? NAFLD/NASH is a multifactorial and multistep disease of uncertain causes. However, several metabolic risk factors, including overweight (BMI ¼ 25-30 kg/m 2 )/obesity (BMI > 30 kg/m 2 ), elevated waist circumference (90th percentile), hypertransaminasaemia [alanine transaminase (ALT) levels 40 IU/l], type 2 diabetes (American Diabetes Association guidelines for children), high cholesterol (>200 mg/dl) and triglyceride (>150 mg/dl) levels and insulin resistance, have been related to NASH development in children [21 ,22,23 ,24] . Unfortunately, estimation of the incidence of these risk factors in NASH pathogenesis is blurred by two common confounding factors associated with the disease: sex and ethnicity. In fact, the prevalence of paediatric NASH peaked at puberty in relation to sex hormones and insulin resistance [25] ; and although the racial/ethnic disparity in NAFLD/NASH prevalence is not determined, it may associate with differences in body composition, insulin sensitivity, adipocytokine profile or other unidentified genetic and environmental factors [26-28].
The etiopathogenesis of NAFLD/NASH has been long disputed. Several authors have been suggested a model consisting of two or more hits. Liver fat accumulation, which is the suggested 'first hit', leads to simple fatty liver and makes the steatotic liver more vulnerable to possible 'second hits', which are responsible for progression to NASH [7] . As shown in Fig. 1 , NASH development and its progression incorporate many causes and different pathogenetic models, which include lifestyle, insulin resistance, imbalance of adipocytokine production/release, increased oxidative stress and endotoxaemia [8,29 ,30 ] . Furthermore, many children, as shown in adults, with fatty liver do not develop NASH; thus, it is possible that environment in combination with genetic factors is required for progression to NASH and fibrosis [30 ,31 ] .
This complicated network of interactions existing among tissues, cells and signalling pathways that lead to NAFLD/NASH makes it almost impossible to distinguish between causes or effects during development and progression of disease [32 ] . Moreover, although predisposing conditions to paediatric NAFLD are similar to those responsible for the adult form (increased BMI and visceral adiposity), the maintenance of the equilibrium between nutrition and adequate physical activity is more complex in children. In fact, in children, the imbalance versus a surplus of calories is spreading due to the daily consumption of fast foods, baked goods, vending machine snacks and soft drinks associated with sedentary free-time activities such as watching television or playing video games rather than engaging in sport activities.
How is nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis currently diagnosed?
The evidence described stresses the need for early diagnosis of NAFLD to prevent the possible development of severe liver disease. At this time, the diagnosis of fatty liver comes from detection of random changes of liver function tests (particularly ALT), generally located in asymptomatic patients in whom the ultrasound findings are suggestive of steatosis in the absence of other reasons for liver disease. However, the only means of proving a diagnosis of NASH and separating it from simple fatty liver is a liver biopsy [5 ,33] .
Although liver biopsy is the 'gold standard' for grading and staging of NAFLD/NASH, its use has several well documented drawbacks. The most important limiting factor of liver biopsy is its invasive nature, which is associated with serious complications (0.3%) and in some cases with mortality (0.01%). As liver biopsy represents only a small portion of the liver, sampling errors, although rare, may also occur. High cost and variability in pathologist's interpretation of liver damage are other limitations to the (utility?) accuracy (?) of liver biopsy for diagnosis of NASH [34].
Noninvasive imaging techniques, currently in use to detect fatty liver, are abdominal ultrasound, computed tomography (CT) scan and magnetic resonance imaging [33, 35 ] .
Abdominal ultrasound is the most commonly used screening test for the diagnosis of fatty liver; however, its sensitivity is limited by the inability to detect the infiltration of fat below 20%, and to differentiate between degrees of the disease and the presence of NASH. Moreover, it should be noted that as BMI increases, sensitivity of ultrasound decreases, implying that a negative ultrasound does not exclude the diagnosis [36 ].
CT is more sensitive than ultrasound in monitoring the fat content but its major limitation lies in the possible masking effect produced by the presence of iron overload, which is frequent in NASH. Furthermore, because of the potential hazards of radiation, CT is considered less appealing, especially in the paediatric age group [33,35 ,37 ] .
More recently, nuclear magnetic resonance spectroscopy has emerged as a fast, well tolerated, noninvasive alternative for the quantification of hepatic fat content, is probably the most sensitive imaging technique and very specific for the diagnosis of NAFLD; however, it does not distinguish between simple steatosis and NASH, more or less complicated by fibrosis, and remains a high-cost technique [33,35 ,37 ] .
Conventional diagnostic imaging methods cannot accurately distinguish NASH from simple steatosis, nor can they assess the severity of fibrosis. However, transient elastography by FibroScan (Echosens, France) has been recently demonstrated to be an accurate and reproducible technique to identify children and adolescents with significant degrees of liver fibrosis [38] .
In recent years, along with imaging techniques, numerous noninvasive serum biomarkers have also been tested in adult and children (Table 1 [ 39,40 ,41-43,44 ,45,46 ] ). Among these serological parameters, apoptosis and fibrosis markers seem to be able to differentiate well between steatosis and NASH in paediatric patients, as well as in adults. In particular, levels of plasma cytokeratin-18 fragments (apoptosis marker), and enhanced liver fibrosis (ELF) panel (including hyaluronic acid, procollagen III amino terminal peptide and tissue inhibitor of metalloproteinase 1), are markedly increased in patients with NASH, and other interesting serum biomarkers are currently under evaluation (see Table 1 ).
Very recently, researchers have cleverly combined the results obtained from these panels of multiple markers with imaging data, and liver function tests (i.e. serum levels of ALT) to generate algorithms able to improve diagnostic accuracy and thus avoid the need for liver biopsy in paediatric NAFLD/NASH [37 ] .
What are the principles of nonalcoholic steatohepatitis children management?
Current therapies are based primarily on modification of the factors involved in the pathogenesis of NAFLD/ NASH. In fact, loss of weight or visceral fat, increasing Insulin resistance [46 ] ELF, enhanced liver fibrosis; PAI-1, plasminogen activator inhibitor 1; RBP4, retinol-binding protein 4; TNFa, tumor necrosis factor-alpha.
insulin sensitivity and ultimately reducing oxidative stress are the main goals of therapy [47 ,48] .
The first approach requires close attention to changes in lifestyle, including diet and exercise. Gradual weight loss and exercise together have been demonstrated to improve ALT levels and liver histology in adults [47 ,48] . However, the rate and degree of weight loss required for normalization of liver histology have not yet been established for paediatric patients, and it has been shown that very rapid weight loss associated with a very low calorie diet can actually worsen the degree of liver inflammation in children with NASH [49 ,50] . Because of the association amongobesity,insulin resistance andNASH, weightreduction by bariatric surgery has also been proposed as potential treatment in obese adolescents with NASH, but such studies in paediatric patients are currently lacking [5 ] .
Another useful approach to potentially revert liver injury through the reduction of steatosis is the treatment with insulin-sensitizing agents such as metformin. Insulin sensitizers have been used successfully to improve insulin resistance and liver histology in adults. In children, unfortunately, the use of insulin-sensitizing agents such as metformin seems to act positively only on the ALT levels [5 ,51] .
The third approach involves the use of antioxidant agents. It was, in fact, suggested that antioxidants are able to reduce oxidative stress and the progression of simple steatosis to NASH. In studies on adults, it was observed that vitamin E improved the ALT and liver histology, whereas in paediatric studies, vitamin E was effective in the ALT normalization but not in reducing the liver damage [50, 52 ] .
Numerous trials are currently underway to evaluate the effect of various other substances (i.e. ursodeoxycholic acid and docosahexaenoic acid) on metabolic disorders and liver damage associated with paediatric NASH (see http://clinicaltrials.gov for reference).
It is noteworthy that recent advances in the understanding of pathogenesis of NAFLD may result, in the not too distant future, in new pharmacological approaches for the treatment of the disease. The association between small intestinal bacterial overgrowth, increased endotoxaemia, activation of Toll-like receptor 4 and steatohepatitis strongly supports the use of prebiotics, probiotics and modulators of the Toll-like receptors as potential future therapy in NAFLD/NASH [53 ] .
Conclusion
In the past 20 years, the knowledge of NASH has been considerably expanded yet diagnosis, prevention and therapy remain critical aspects in the management of this disease. To date, the exact strategy for the treatment of NAFLD/NASH has yet to be established; thus, research in this area is another important challenge. Several registered drugs (i.e. antibiotics, immunosuppressive agents and probiotics) should be further investigated to evaluate their antisteatotic or antifibrogenic effects.
Because early diagnosis and intervention are critical in patients with NASH, there is a need for improvement of the diagnostic value of noninvasive tests by integration with other interesting circulating biomarkers, and preventive strategies for limiting risk factors for fatty liver or its progression should be instituted [54 ] .
We believe that the design and translation into clinical practice of indices that integrate noninvasive diagnostic tools and serum biomarkers will be the main objectives for improving the therapeutic management of NAFLD/ NASH in the coming years.
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